Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ian Baxter

Obstetrics & Gynecology Seaford, DE Doctor of Osteopathy

NPI 1902890148 CMS profile 901404

100 Rawlins Drive, Seaford, DE 19973

Open in the dashboard

General payments

$156,822

258 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ian Baxter of Seaford, DE is reported in the CMS Open Payments database as having received $156,822 across 258 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,666 41
2024 General $12,209 27
2023 General $16,408 32
2022 General $37,297 64
2021 General $24,029 23
2020 General $6,172 9
2019 General $39,041 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ian Baxter
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Ian Baxter were reported at $21,666. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Ian Baxter Obstetrics & Gynecology median Middle half National median
2019 $39,041 $172 $62–$391 $163
2020 $6,172 $94 $36–$222 $114
2021 $24,029 $136 $42–$369 $132
2022 $37,297 $160 $50–$433 $149
2023 $16,408 $169 $56–$423 $160
2024 $12,209 $152 $50–$371 $164
2025 $21,666 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organon LLC $69,899 71 payments
  2. Merck Sharp & Dohme Corporation $38,579 63 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $28,321 37 payments
  4. Biogen, Inc. $9,800 8 payments
  5. Lupin Inc. $8,788 7 payments
  6. Evofem Biosciences, Inc. $261 14 payments
  7. Myovant Sciences Inc. $214 10 payments
  8. Sumitomo Pharma America, Inc. $170 9 payments
  9. Sage Therapeutics, Inc. $160 8 payments
  10. AbbVie, Inc. $151 9 payments
  11. Other $478 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $81,394 52 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $54,714 51 payments
  3. Consulting Fee $11,594 5 payments
  4. Travel and Lodging $6,524 37 payments
  5. Food and Beverage $2,596 113 payments
Products named General payments · program years 2019–2025
  1. NEXPLANON Etonogestrel $49,311 52 payments
  2. NEXPLANON Womens Health $38,525 61 payments
  3. Nexplanon Womens Health $15,056 14 payments
  4. Kyleena Womens Health $10,046 18 payments
  5. SOLOSEC $8,788 7 payments
  6. Zurzuvae $7,658 7 payments
  7. Kyleena Women's Health $6,824 9 payments
  8. Mirena $5,533 12 payments
  9. Lynkuet $1,600 1 payment
  10. Skyla $1,212 1 payment
  11. Other $1,734 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$8,869

Medicare's payments for the services billed

Medicare patients

55

Average age 66

Services billed

132

55 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $51
$51 — —
SLYND
  • Exeltis, USA Inc. $36
$36 — —
MYFEMBREE
  • PFIZER INC. $17
  • Sumitomo Pharma America, Inc. $16
$33 — —
GARDASIL 9
  • Merck Sharp & Dohme Corporation $13
$13 — —
GARDASIL
  • Merck Sharp & Dohme Corporation $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

258 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record